Obese man treated with drotrecogin alfa (activated) [3]

Annals of Pharmacotherapy

Volumn 37, Issue 6, 2003, Pages 918-919

  Loveland, Scott M ^a   Lewin III, John J ^b   Amabile, Celene M ^c   Strange, Charlie ^c   Mazur, Joseph E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

ADULT; CASE REPORT; CLINICAL FEATURE; DEATH; DISEASE COURSE; DOSE CALCULATION; DRUG CLEARANCE; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LETTER; MALE; MULTIPLE ORGAN FAILURE; OBESITY; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0038147215     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C478     Document Type: Letter

References (5)

1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
2. Snider RD, Kruse JA, Bander JJ, Dunn GH. Accuracy of estimated creatinine clearance in obese patients with stable renal function in the intensive care unit. Pharmacotherapy 1995;15:747-53.
3. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999;88:1-7.
4. Cheymol G. Clinical pharmacokinetics of drugs in obesity - an update. Clin Pharmacokinet 1993;25:103-14.
5. Macias WL, Dhainaut JF, Yan SCB, Helterbrand JD, Seger M, Johnson G, et al. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clinical Pharm Ther 2002;72:391-402.